

PTC/SB/08A				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/023,401
				Filing Date	February 12, 1998
				Confirmation Number	6896
				First Named Inventor	Gary S. Jacob
				Group Art Unit	
				Examiner Name	R. Travers
Sheet	1	of	1	Attorney Docket No.	PHA 6067



RECEIVED
TECH CENTER 1800/2900
APR 02 2002

U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁶	
		Number	Kind Code ² (if known)				
	186	4,940,705	B	Böshagen, et al.	07-10-1990		
	187	5,051,407	B	Böshagen, et al.	09-24-1991		
FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁶
		Office	Number ⁴	Kind Code ² (if known)			
	188	PCT	WO91/03242	A1	Nippon-Shinyaku-Co. Ltd.	03-21-1991	
	189	PGT	WO00/47498	A2	G.D. Searle & Co.	08-17-2000	
OTHER ART - NON PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.					T ⁶
	190	MUELLER, R. et al., "Use of N-substituted 1,5-dideoxy-1,5-imino-D-glucitol compounds for treating hepatitis virus infections," CA 135:175348, 2001					

Examiner Signature		Date Considered	3/12/02
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.



INFORMATION DISCLOSURE STATEMENT
BY APPLICANT(S)
(Use several sheets if necessary)

Sheet 1 of 3

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<i>b</i>	147	4,269,857	5/1981	Tokuda et al.	424	325	
<i>b</i>	148	5,221,746	6/1993	Partis et al.	546	220	
	149	5,264,356	11/1993	Rohrschneider	435	236	
	150	5,622,972	4/1997	Bryant et al.	514	315	
	151	5,703,058	12/1997	Schinazi et al.	514	45	
	152	6,093,702	7/2000	Malley et al.	514	45	

FOREIGN PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	153	2,700,267	1/1993	FR	A61K	9/107		
	154	0,401,194	6/1990	EPO	A61K	31/70		
	155	0,477,160	9/1991	ERO	C12P	17/04		
	156	0,691,327	3/1994	EPO	C07C	217/28		
	157	0,729,747	2/1996	EPO	A61K	7/48		
	158	WO91/47445	11/1991	PCT	C07D	211/46		
	159	WO94/04546	3/1994	PCT	C07H	17/02		Abstract
	160	WO95/06061	3/1995	PCT	C07K	5/03		
	161	WO99/29321	6/1999	PCT	A61K	31/445		
	162	WO99/40916	8/1999	PCT	A61K	31/445		

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

163	Acosta et al., "Agents for Treating Human Immunodeficiency Virus Infection," Am. J. Hosp. Pharm., Vol. 51, September 15, 1994, pp. 2251-2287
164	Tennant et al., "Animal Models in the Preclinical Assessment of Therapy for Viral Hepatitis," Antiviral Therapy, Vol. 1, (Suppl. 4), 1996, pp. 47-52

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT(S)
(Use several sheets if necessary)

Sheet 2 of 3



APPLICANT

Gary S. Jacob et al.

FILING DATE

February 12, 1998

GROUP

1614

ECR CENTER 1600/2900

JUL 23 2001

165	Sachs, "Antiretroviral Chemotherapy of Human Immunodeficiency Virus Infections Other Than with Azidothymidine," Arch. Inter. Med., Vol. 152, March 1992, pp. 485-501
166	Gasparini, et al., "Clinical Importance of the Determination of Tumor Angiogenesis in Breast Carcinoma: Much More Than a New Prognostic Tool," Journal of Clinical Oncology, Vol. 13, No. 3, March 1995, pp. 765-782
167	Bruyneel, et al., "Effect of Glycosylation Inhibitors on N-Glycosylpeptides and on Invasion of Malignant Mouse MO ₃ Cells in Vitro," Journal of Cell Science, Vol. 95, 1990, pp. 279-286
168	Jacob, "Glycosylation Inhibitors in Biology and Medicine," Current Opinion in Structural Biology, No. 5, 1995, pp. 605-611
169	Senuma, et al., "Highly Effective Resolution of 1,3-Dibenzyl-6-hydroxy-3,3a,6,6a-tetrahydro-1H-furo[3,4-d]imidazole-2,4-dione, an Intermediate for Biotin, with Optically-Active Amines and Reutilization of the Unwanted Epimer," Chem. Pharm. Bull., Vol. 38, No. 4, 1990, pp. 882-887
170	Zitzmann, et al., "Imino Sugars Inhibit the Formation and Secretion of Bovine Viral Diarrhea Virus, a Pestivirus Model of Hepatitis C Virus: Implications for the Development of Broad Spectrum Anti-Hepatitis Virus Agents," PNAS, Vol. 96, No. 21, October 12, 1999, pp. 11878-11882
171	Jacob, et al., "Iminosugar alpha-Glucosidase Inhibitors as Drugs and Pro-Drugs for Treatment of HIV Infections," Washington Book of Abstracts, 208th ACS National Meeting, August 21-25, 1994, one page
172	Rusconi, et al., "Inhibition of Human Immunodeficiency Virus Type I Replication in Cytokine-Stimulated Monocytes/Macrophages by Combination Therapy," Journal of Infectious Diseases, Vol. 170, 1994, pp. 1361-1366
173	Goss, et al., "Inhibitors of Carbohydrate Processing: A New Class of Anticancer Agents," Clinical Cancer Research, Vol. 1, September 1995, pp. 935-944
174	Isom, et al., "Molecular Pathology of Human Oncogenic Viruses," Cellular and Molecular Pathogenesis, Chapter 14, 1996, pp. 341-387
175	Ratner, et al., "Mechanism of Action of N-Butyl Deoxynojirimycin in Inhibiting HIV-1 Infection and Activity in Combination with Nucleoside Analogs," AIDS Research and Human Retroviruses, Vol. 9, No. 4, 1993, pp. 291-297
176	Myers, "New Antiretroviral Agents in the Clinic," Reviews of Infectious Diseases, Vol. 12, No. 5, September/October 1990, pp. 944-950
177	Yangco, et al., "Pilot Safety and Efficacy of Combination SC-48334 (N-Butyl-Deoxynojirimycin (NB-DNJ) and Zidovudine (ZDA) in Symptomatic HIV-1 Infected Patients with >200 - <500 CD4 Cells/mm ³ ," Abstracts of the 1st National Conference on Human Retroviruses, Session 86, Abstract No. 574, p. 160
178	van den Broek, et al., "Synthesis of Oxygen-Substituted N-alkyl 1-deoxynojirimycin derivatives: aza sugar alpha-glucosidase inhibitors showing antiviral (HIV-1) and immunosuppressive activity," Recl. Trav. Chim. Pays-Bas 113, 1994, pp. 507-516
179	Mills, et al., "The Reaction of Glucose with Some Amines," Journal of the American Chemical Society, Vol. 66, March 1944, pp. 483-486
180	Fischl, et al., "The Preliminary Efficacy and Safety of N-Butyl-Deoxynojirimycin (SC-48334), an alpha-Glucosidase I Inhibitor, in Combination with Zidovudine (ZDA)," International Conference on AIDS, Berlin, June 6-11, 1993, one page

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT(S)
(Us s veral sh ets If n cessary)

Sheet 3 of 3



181	Filino, "Treatment of Chronic Viral Hepatitis," Mol. Med. (Tokyo), 1996, Vol. 33, No. 3, pp. 276-286 (English language abstract only)
182	Fiume, et al., "Targeting of Antiviral Drugs to the Liver Using Glycoprotein Carriers," Advanced Drug Delivery Reviews, Vol. 14, 1994, pp. 51-65
183	Mutchnick, et al., "Thymosin Treatment of Chronic Active Hepatitis B (CAHB): A Preliminary Report on a Controlled, Double Blind Study," 1988, Hepatology, Vol. 8, No. 5, Article 208, p. 1270
184	Jones, et al., "Use of the Topliss Scheme for the Design of More Effective Chelating Agents for Cadmium Decorporation," Chem. Res. Toxicol., Vol. 1, 1988, pp. 234-237
185	Karrer, et al., "Zur Kenntnis der Reduktionsprodukte aus Aromatischen Aminen und Zuckern," 1935, p. 1338-1340


EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. SRL 6067	SERIAL NO. 09/023,401		
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT Gary S. Jacob			
Ant in 09/249,220?				FILING DATE 2-12-98	GROUP 1614		
U.S. PATENT DOCUMENTS							
RECEIVED							
*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		3,590,028	6/1971	Arcamone	260	210	TECH CENTER 1600/2900
		4,042,448	3/1977	Smith et al.	260	591	
		4,065,562	12/1977	Ohata et al.	424	267	
		4,182,767	1/1980	Murai et al.	424	267	
		4,260,622	4/1981	Junge et al.	424	267	
		4,327,725	5/1982	Cortese et al.	128	260	
		4,524,060	6/1985	Mughal et al.	424	19	
		4,533,668	8/1985	Matsumura et al.	514	321	
		4,611,058	9/1986	Koebernack	546	242	
		4,612,008	9/1986	Wong et al.	604	892	
		4,765,989	8/1988	Wong et al.	424	473	
		4,783,337	11/1988	Wong et al.	424	468	
		4,806,650	2/1989	Schröder et al.	546	242	
	B	4,849,430	7/1989	Fleet et al.	514	315	
		4,880,830	11/1989	Rhodes	424	470	
		4,957,926	9/1990	Jacob et al.	514	315	
	B	5,003,072	3/1991	Partis et al.	546	243	
		5,011,829	4/1991	Hirsch et al.	514	50	
		5,030,638	7/1991	Partis et al.	514	315	
		5,041,441	8/1991	Radin et al.	514	237.8	
		5,068,112	11/1991	Samejima et al.	424	495	
		5,190,765	3/1993	Jao et al.	424	473	
	7	5,144,037	9/1992	Partis et al.	546	116	


EXAMINER RSJ	DATE CONSIDERED 7/26/01
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>	


FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. SRL 6067		SERIAL NO. 09/023,401	
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT Gary S. Jacob			
				FILING DATE 2-12-98		GROUP 1614	

50	5,151,519	9/1992	Behling et al.	546	219	
51	5,281,724	4/1994	Behling et al.	549	334	
52	5,310,745	5/1994	Partis et al.	514	315	
53	5,331,096	7/1994	Koszyk et al.	546	115	
54	5,411,970	5/1995	Partis et al.	514	315	
55	5,454,679	9/1995	Barta et al.	546	219	
56	5,472,969	12/1995	Platt et al.	514	315	
57	5,491,135	2/1996	Blough	514	115	
58	5,525,016	6/1996	Platt et al.	514	315	
59	5,536,732	7/1996	Lesur et al.	514	317	
60	5,595,984	1/1997	Barta et al.	514	63	
61	5,612,480	3/1997	Barta et al.	544	180	
62	5,663,342	9/1997	Barta et al.	546	6	


FOREIGN PATENT DOCUMENTS								
EXAMINER INITIAL		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
		2,020,278	3/1979	U.K.	C07D	211/40		
		0,324,328	7/1989	EPO	A61K	31/445		
		0,350,012	1/1990	EPO	A61K	31/445		
		0,367,748	5/1990	EPO	C07D	211/46		
		0,449,026	10/1991	EPO	C07D	491/04		
		0,494,850	7/1992	EPO	C07D	211/46		
		0,566,556	10/1993	EPO	C07D	211/40		
		WO87/03903	7/1987	PCT	C12N	05/00		
		WO95/22975	8/1995	PCT	A61K	31/445		
		WO96/40110	12/1996	PCT	A61K	31/35		

EXAMINER 	DATE CONSIDERED <u>9/26/01</u>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. SRL 6067		SERIAL NO. 09/023,401	
LIST OF PRIOR ART CITED BY APPLICANT (Us sev ral sh ts If nec ssary)							
APPLICANT Gary S. Jacob				FILING DATE 2-12-98		GROUP 1614	
73	WO97/00884	11/1997	PCT	C07H	17/02		No
74	WO98/35685	8/1998	PCT	A61K	31/70		
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
75	Dalton, et al., "A Phase II Randomized Study of Oral Verapamil as a Chemosensitizer to Reverse Drug Resistance in Patients with Refractory Myeloma," February 1, 1995, Cancer, Vol. 75, No. 3, pp. 815-820						
76	Jacob et al., "Aminosugar Attenuation of HIV Infection," 1992, Natural Products as Antiviral Agents, pp. 137-152						
77	Karpas, et al., "Aminosugar Derivatives as Potential Anti-Human Immunodeficiency Virus Agents," December, 1988, Proc. Natl. Acad. Sci., Vol. 85, pp. 9229-9233						
78	Welsh, et al., "Accumulation of Fatty Alcohol in MCF-7 Breast Cancer Cells," November 15, 1994, Archives of Biochemistry and Biophysics, Vol. 315, No. 1, pp. 41-47						
79	Lavie, et al., "Agents that Reverse Multidrug Resistance, Tamoxifen, Verapamil, and Cyclosporin A, Block Glycosphingolipid Metabolism by Inhibiting Ceramide Glycosylation in Human Cancer Cells," August 20, 1996, The Journal of Biological Chemistry, Vol. 272, No. 3, pp. 1682-1687						
80	Lavie, et al., "Accumulation of Glucosylceramides in Multidrug-Resistant Cancer Cells," August 9, 1996, The Journal of Biological Chemistry, Vol. 271, No. 32, pp. 19530-19536						
81	Inokuchi, et al., "Antitumor Activity Via Inhibition of Glycosphingolipid Biosynthesis," September 3, 1987, Cancer Letters, Vol. 38, pp. 23-30						
82	Holleran, et al., "Characterization of Cellular Lipids in Doxorubicin-Sensitive and -Resistant P388 Mouse Leukemia Cells," 1986, Cancer Chemother Pharmacol, 17:11-15						
83	Fisher, et al., "Clinical Studies with Modulators of Multidrug Resistance," April 1995, Drug Resistance in Clinical Oncology and Hematology, Vol. 9, No. 2, pp. 363-382						
84	Raderer, et al., "Clinical Trials of Agents that Reverse Multidrug Resistance," December 15, 1993, Cancer, Vol. 72, No. 12, pp. 3553-3563						
85	Tan, et al., "Chemical Modification of the Glucosidase Inhibitor 1-Deoxynojirimycin," August 5, 1991, The Journal of Biological Chemistry, Vol. 266, No. 22, pp. 14504-14510						
86	Wang, et al., "Chemo-enzymatic Synthesis of Five-membered Azasugars as Inhibitors of Fucosidase and Fucosyltransferase: An Issue Regarding The Stereochemistry Discrimination at Transition States," 1993, Tetrahedron Letters, Vol. 34, No. 3, pp. 403-406						
87	Jezowska-Bejczuk, et al., "Copper(II) Interactions with an Experimental Antiviral Agent, 1-Deoxynojirimycin, and Oxygen Activation by Resulting Complexes," 1996, Journal of Inorganic Biochemistry, Vol. 64, pp. 231-246						
88	Ramu, et al., "Differences in Lipid Composition of Doxorubicin-Sensitive and -Resistant P388 Cells," April 1984, Cancer Treatment Reports, Vol. 68, No. 4, pp. 637-641						

EXAMINER 	DATE CONSIDERED 1/26/05
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>	

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. SRL 6067	SERIAL NO. 09/023,401
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT Gary S. Jacob	
				FILING DATE 2-12-98	GROUP 1614




89		Beketic-Oreskovic, et al., "Decreased Mutation Rate for Cellular Resistance to Doxorubicin and Suppression of mdr1 Gene Activation by the Cyclosporin PSC 833," November 1, 1995, Journal of the National Cancer Institute, Vol. 87, No. 21, pp. 1593-1602
90		Volm, et al., "Expression of Resistance Factors (P-Glycoprotein, Glutathione S-Transferase-II, and Topoisomerase II) and Their Interrelationship to Proto-Oncogene Products in Renal Cell Carcinomas," June 15, 1993, Cancer, Vol. 71, No. 12, pp. 3981-3987
91		Lu, et al., "Evidence That N-Linked Glycosylation is Necessary for Hepatitis B Virus Secretion," November 10, 1995, Virology, Vol. 213, No. 2, pp. 660-665
92		Legler, et al., "Glycosylceramidase from Calf Spleen: Characterization of its Active Site with 4-n-Alkylumbelliferyl β -glucoside and N-alkyl Derivatives of 1-Deoxynojirimycin," December 1985, Bio-ChemHoppe-Seyler, Vol. 366, pp. 1113-1122
93		Hardman, et al., "Goodman & Gilman's The Pharmacological Basis of Therapeutics," 1996, McGraw-Hill, Ninth Edition, Chapter 32: Drugs Used for the Treatment of Myocardial Ischemia," Verapamil, pp. 767-774, 780-781, 799-801, and 829
94		Mehta, et al., Hepatitis B Virus (HBV) Envelope Glycoproteins Vary Drastically in Their Sensitivity to Glycan Processing: Evidence that Alteration of a Single N-Linked Glycosylation Site Can Regulate HBV Secretion," March 1997, Proc. Natl. Acad. Sci., Vol. 94, pp. 1822-1827
95		Hollinger, "Hepatitis B Virus," Field Virology, Third Edition, Chapter 86, pp. 2739-2807
96		Fleet, et al., "Inhibition of HIV Replication by Amino Sugar Derivatives," September 1988, Federation of European Biochemical Societies, Vol. 237, No. 1,2, pp. 128-132
97		Newbrun, et al., "Inhibition by Acarbose, Nojirimycin and 1-Deoxynojirimycin of Glucosyltransferase Produced by Oral Streptococci," 1983, Archs Oral Biol., Vol. 28, No. 6, pp. 531-536
98		Saunier, et al., "Inhibition of N-Linked Complex Oligosaccharide Formation by 1-Deoxynojirimycin, An Inhibitor of Processing Glucosidases," December 10, 1982, The Journal of Biological Chemistry, Vol. 257, No. 23, pp. 14155-14161
99		Abe, et al., "Induction of Glycosylceramide Synthase by Synthase Inhibitors and Ceramide," 1996, Biochemica et Biophysica Acta, Vol. 1299, pp. 333-341
100		Abe, et al., "Improved Inhibitors of Glucosylceramide Synthase," 1992, J. Biochem., Vol. 111, pp. 191-196
101		Elbein, "Inhibitors of the Biosynthesis and Processing of N-Linked Oligosaccharide Chains," 1987, Ann. Rev. Biochem., 56:497-534
102		Radin, et al., "Inhibitors of Cerebroside Metabolism," 1981, Methods in Enzymology, Vol. 72, pp. 673-684
103		Prencipe, et al., "In Vitro Accumulation of Glucocerebroside in Neuroblastoma Cells: A Model for Study of Gaucher Disease Pathobiology," 1996, Journal of Neuroscience Research, 43:365-371

EXAMINER S. V. J.	DATE CONSIDERED 1/28/05
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. SRL 6067	SERIAL NO. 09/023,401
LIST OF PRIOR ART CITED BY APPLICANT (Us s veral she ts If n c ssary)				APPLICANT Gary S. Jacob	
				FILING DATE 2-12-98	GROUP 1614
	104	Bradley, et al., "Mechanism of Multidrug Resistance," 1988, Biochimica et Biophysica Acta, Vol. 948, pp. 87-128			
	105	Molder, et al., "Multidrug Resistance-Modifying Components in Human Plasma with Potential Clinical Significance," January 1996, Journal of Experimental Therapeutics & Oncology, Vol. 1, No. 1, pp. 13-22			
	106	Ardalan, et al., "Mechanism of Action of a New Antitumor Agent, Carbimide," November, 1986, Cancer Research, Vol. 46, pp. 5473-5476			
	107	Platt, et al., "Modulation of Cell-Surface Transferrin Receptor by the Imino Sugar N-butyldeoxynojirimycin," 1992, Eur. J. Biochem., Vol. 208, pp. 187-193			
	108	Kawakami, et al., "Monoclonal Antibodies with Affinity to Self-Complementary Left-Handed DNA Containing Cyclonucleosides with High Anti Conformation," 1994, Nucleosides & Nucleotides, Vol. 13(1-3), pp. 421-427			
	109	Dicato, et al., "Multidrug Resistance: Molecular and Clinical Aspects," 1997, Cytokines, Cellular & Molecular Therapy, Vol. 3, No. 2, pp. 91-100			
	110	Bolhuis, et al., "Mechanisms of Multidrug Transporters," 1997, FEMS Microbiology Reviews, Vol. 21, pp. 55-84			
	111	Carbohydrate Chemistry, Chapter 20: Nucleosides, undated, pp. 242-276			
	112	Platt, et al., "N-Butyldeoxynojirimycin is a Novel Inhibitor of Glycolipid Biosynthesis," March 18, 1994, The Journal of Biological Chemistry, Vol. 269, No. 11, pp. 8362-8365			
	113	Platt, et al., "N-Butyldeoxygalactonojirimycin Inhibits Glycolipid Biosynthesis but Does Not Affect N-Linked Oligosaccharide Processing," October 28, 1994, The Journal of Biological Chemistry, Vol. 269, No. 43, pp. 27108-27114			
	114	Platt, et al., "New Approach for the Treatment of Gauchers Disease," March 1996, Gauchers Association Newsletter, one page			
	115	Wilson, et al., "Nitrogen Glycosylation Reactions Involving Pyrimidine and Purine Nucleoside Bases with Furanoside Sugars," December 1995, Synthesis, Department of Chemistry, Emory University, pp. 1465-1479			
	116	Kers, et al., "Nucleoside Phosphonates: Development of Synthetic Methods and Reagents," 1996, Nucleosides & Nucleotides, 15(1-3), pp. 361-378			
	117	Tsuruo, et al., "Overcoming of Vincristine Resistance in P388 Leukemia: In Vivo and In Vitro Enhanced Cytotoxicity of Vincristine and Vinblastine by Verapamil," May 1981, Cancer Research, Vol. 41, pp. 1967-1972			
	118	Wright, et al., "Phospholipid and Ether Linked Phospholipid Content Alter with Cellular Resistance to Vinblastine," December 17, 1985, Biochemical and Biophysical Research Communications, Vol. 133, No. 2, pp. 539-545			
	119	Bradley, et al., "P-glycoprotein, Multidrug Resistance and Tumor Progression," 1994, Cancer and Metastasis Reviews, Vol. 13, pp. 223-233			
	120	May, et al., "Plasma Membrane Lipid Composition of Vinblastine Sensitive and Resistant Human Leukaemic Lymphoblasts," 1988, Int. J. Cancer, Vol. 42, pp. 728-733			

EXAMINER	<i>H. J. Jones</i>	DATE CONSIDERED	<i>1/24/05</i>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. SRL 6067	SERIAL NO. 09/023,401
LIST OF PRIOR ART CITED BY APPLICANT (Us s v r a l s h e t s I f n e c e s s a r y)				APPLICANT Gary S. Jacob	
				FILING DATE 2-12-98	GROUP 1614
	121	Platt, et al., "Prevention of Lysosomal Storage in Tay-Sachs Mice Treated with N-Butyldoxynojirimycin," April 18, 1997, Science, Vol. 276, pp. 428-431			
	122	Wishart, et al., "Quinidine as a Resistance Modulator of Epirubicin in Advanced Breast Cancer: Mature Results of a Placebo-Controlled Randomized Trial," September 1994, Journal of Clinical Oncology, Vol. 12, No. 9, pp. 1771-1777			
	123	Chabner, et al., "Reversal of Multidrug Resistance," January 1991, Journal of Clinical Oncology, Vol. 9, No. 1, pp. 4-6			
	124	Hui, et al., "Reduced p21^{WAF1/CIP1} Expression and p53 Mutation in Hepatocellular Carcinomas," March 1997, Hepatology, Vol. 25, No. 3, pp. 575-579			
	125	Radin, "Rationales for Cancer Chemotherapy with PDMP, a Specific Inhibitor of Glucosylceramide Synthase," 1994, Molecular and Chemical Neuropathology, Vol. 21, pp. 111-127			
	126	Arends, "Recueil des Travaux Chimiques des Pays-Bas," Journal of the Royal Netherlands Chemical Society, February 1994, Recl. Trav. Chim. Pays-Bas 113, 63-114, contents page only			
	127	Shukla, et al., "Rapid Kidney Changes Resulting from Glycosphingolipid Depletion by Treatment with a Glucosyltransferase Inhibitor," 1991, Biochimica et Biophysica Acta, Vol. 1083, pp. 101-108			
	128	Block, et al., "Secretion of Human Hepatitis B Virus is Inhibited by the Imino Sugar N-butyldoxynojirimycin," March 1994, Proc. Natl. Acad. Sci., Vol. 91, pp. 2235-2239			
	129	Inokuchi, et al., "Stimulation of Glycosphingolipid Biosynthesis by L-Threo-1-Phenyl-2-Decanoylamino-1-Propanal and Its Homologs in B16 Melanoma Cells," 1995, J. Biochem., Vol. 117, No. 4, pp. 766-773			
	130	Abe, et al., "Structural and Stereochemical Studies of Potent Inhibitors of Glucosylceramide Synthase and Tumor Cell Growth," 1995, Journal of Lipid Research, Vol. 36, pp. 611-621			
	131	Ogawa, et al., "Synthesis of Potent β -D-Glucocerebrosidase Inhibitors: N-Alkyl- β -Valienamines," 1996, Bioorganic & Medicinal Chemistry Letters, Vol. 6, No. 8, pp. 929-932			
	132	Vorbrüggen, et al., "Some Recent Trends and Progress in Nucleoside Synthesis," 1996, Acta Biochimica Polonica, Vol. 43, No. 1, pp. 25-36			
	133	Sobrero, et al., "Sequential Dichloromethotrexate (DCM) and 5-Fluorouracil (FU): A Synergistic Combination Potentially Valuable for Hepatic Artery Infusion Therapy," March 1983, ASCO Abstracts, Clinical Pharmacology, Vol. 2, Article C-102, p. 26			
	134	Wadkins, et al., "The Role of Drug-Lipid Interactions in the Biological Activity of Modulators of Multi-Drug Resistance," 1993, Biochimica et Biophysica Acta, Vol. 1153, pp. 225-236			
	135	Dejge, et al., "The Effects of Lipids and Detergents on ATPase-Active P-Glycoprotein," 1993, Biochimica et Biophysica Acta, Vol. 1146, pp. 65-72			
	136	Ries, et al., "Treatment of Advanced and Refractory Breast Cancer with Doxorubicin, Vincristine and Continuous Infusion of Verapamil. A Phase I-II Clinical Trial," 1991, Med. Oncol. & Tumor Pharmacother, Vol. 8, No. 1, pp. 39-43			

EXAMINER		DATE CONSIDERED	1/28/05
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. SRL 6067	SERIAL NO. 09/023,401
LIST OF PRIOR ART CITED BY APPLICANT (Us several sheets if nec ssary)				APPLICANT Gary S. Jac b	
				FILING DATE 2-12-98	GROUP 1614
	137	Radin, et al., "Treatment of Gaucher Disease with an Enzyme Inhibitor," 1996, Glycoconjugate Journal, Vol. 13, pp. 153-157			
	138	Fischl, et al., "The Safety and Efficacy of Combination N-Butyl-Deoxynojirimycin (SC-48334) and Zidovudine in Patients with HIV-1 Infection and 20-500 CD4 Cells/mm³," 1994, Journal of Acquired Immune Deficiency Syndromes, Vol. 7, pp. 139-147			
	139	Block, et al., "The Secretion of Human Hepatitis B Virus is Inhibited by the Imino Sugar, N-Butyl-Deoxynojirimycin," undated, Jefferson Cancer Institute, et al., No. 81, one page			
D	140	Mutchnick, et al., "Thymosin Treatment of Chronic Hepatitis B: A Placebo-controlled Pilot Trial," 1991, Hepatology, Vol. 14, No. 3, pp. 409-415			
	141	Simon, et al., "Treatment of Chronic Hepatitis C with Interferon Alfa-n3: A Multicenter, Randomized, Open-Label Trial," February 1997, Hepatology, Vol. 25, No. 2, pp. 445-448			
	142	Cabot, et al., "Tamoxifen Retards Glycosphingolipid Metabolism in Human Cancer Cells," 1996, FEBS Letters (17548), Vol. 394, pp. 129-131			
	143	Lindsay, et al., "Thymosin α_1 Treatment of Chronic Hepatitis B: A Multicenter, Randomized, Placebo-Controlled Double Blind Study," April 1995, AASLD, A1127, one page			
	144	Mutchnick, et al., "Thymosin Treatment of Chronic Active Hepatitis B (CAHB): A Preliminary Report on a Controlled, Double Blind Study," 1988, Hepatology, Vol. 8, No. 5, Article 208, p. 1270			
D	145	Dwek, Raymond, "Glycobiology: Toward Understanding the Function of Sugars," Chem. Rev. 1996, 96, pp. 683-720			
D	146	Platt, Frances M., et al., "Inhibitors of Glycosphingolipid Biosynthesis," Trends in Glycoscience and Glycotechnology, Vol. 7, No. 38, November 1995, pp. 495-511			

EXAMINER	S. V. 1/24/05	DATE CONSIDERED	1/24/05
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			